These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 14673998)

  • 1. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations.
    Stohl W; Metyas S; Tan SM; Cheema GS; Oamar B; Xu D; Roschke V; Wu Y; Baker KP; Hilbert DM
    Arthritis Rheum; 2003 Dec; 48(12):3475-86. PubMed ID: 14673998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus.
    Morel J; Roubille C; Planelles L; Rocha C; Fernandez L; Lukas C; Hahne M; Combe B
    Ann Rheum Dis; 2009 Jun; 68(6):997-1002. PubMed ID: 18676986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.
    Cheema GS; Roschke V; Hilbert DM; Stohl W
    Arthritis Rheum; 2001 Jun; 44(6):1313-9. PubMed ID: 11407690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response.
    Cambridge G; Isenberg DA; Edwards JC; Leandro MJ; Migone TS; Teodorescu M; Stohl W
    Ann Rheum Dis; 2008 Jul; 67(7):1011-6. PubMed ID: 17962238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of the expression levels of BLyS and its receptors mRNA in patients with systemic lupus erythematosus.
    Ju S; Zhang D; Wang Y; Ni H; Kong X; Zhong R
    Clin Biochem; 2006 Dec; 39(12):1131-7. PubMed ID: 17069785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B lymphocyte stimulator expression in pediatric systemic lupus erythematosus and juvenile idiopathic arthritis patients.
    Hong SD; Reiff A; Yang HT; Migone TS; Ward CD; Marzan K; Shaham B; Phei WC; Garza J; Bernstein B; Stohl W
    Arthritis Rheum; 2009 Nov; 60(11):3400-9. PubMed ID: 19877053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus.
    Petri M; Stohl W; Chatham W; McCune WJ; Chevrier M; Ryel J; Recta V; Zhong J; Freimuth W
    Arthritis Rheum; 2008 Aug; 58(8):2453-9. PubMed ID: 18668552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse.
    Cambridge G; Stohl W; Leandro MJ; Migone TS; Hilbert DM; Edwards JC
    Arthritis Rheum; 2006 Mar; 54(3):723-32. PubMed ID: 16508933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosus.
    Carter RH; Zhao H; Liu X; Pelletier M; Chatham W; Kimberly R; Zhou T
    Arthritis Rheum; 2005 Dec; 52(12):3943-54. PubMed ID: 16320342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus.
    Stohl W; Metyas S; Tan SM; Cheema GS; Oamar B; Roschke V; Wu Y; Baker KP; Hilbert DM
    Ann Rheum Dis; 2004 Sep; 63(9):1096-103. PubMed ID: 15308519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of B-cell activating factor of the tumour necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus: the role of BAFF in T cell-dependent B cell pathogenic autoantibody production.
    Morimoto S; Nakano S; Watanabe T; Tamayama Y; Mitsuo A; Nakiri Y; Suzuki J; Nozawa K; Amano H; Tokano Y; Kobata T; Takasaki Y
    Rheumatology (Oxford); 2007 Jul; 46(7):1083-6. PubMed ID: 17500077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosus.
    Toubi E; Kessel A; Rosner I; Rozenbaum M; Paran D; Shoenfeld Y
    Scand J Immunol; 2006 Apr; 63(4):299-303. PubMed ID: 16623930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated expression of the Brn-3a and Brn-3b transcription factors in systemic lupus erythematosus correlates with antibodies to Brn-3 and overexpression of Hsp90.
    Ripley BJ; Rahman MA; Isenberg DA; Latchman DS
    Arthritis Rheum; 2005 Apr; 52(4):1171-9. PubMed ID: 15818685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B lymphocyte stimulator expression in patients with rheumatoid arthritis treated with tumour necrosis factor alpha antagonists: differential effects between good and poor clinical responders.
    La DT; Collins CE; Yang HT; Migone TS; Stohl W
    Ann Rheum Dis; 2008 Aug; 67(8):1132-8. PubMed ID: 17967830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders.
    Novak AJ; Grote DM; Ziesmer SC; Kline MP; Manske MK; Slager S; Witzig TE; Shanafelt T; Call TG; Kay NE; Jelinek DF; Cerhan JR; Gross JA; Harder B; Dillon SR; Ansell SM
    J Clin Oncol; 2006 Feb; 24(6):983-7. PubMed ID: 16432079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expression and clinical significance of inducible co-stimulator on peripheral blood T lymphocyte subsets in patients with systemic lupus erythematosus].
    Yang JH; Shen Q; Zhao DB; Cai Q; Han XH
    Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(5):318-23. PubMed ID: 15854508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis.
    Tan SM; Xu D; Roschke V; Perry JW; Arkfeld DG; Ehresmann GR; Migone TS; Hilbert DM; Stohl W
    Arthritis Rheum; 2003 Apr; 48(4):982-92. PubMed ID: 12687540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis on the association of human BLYS (BAFF, TNFSF13B) polymorphisms with systemic lupus erythematosus and rheumatoid arthritis.
    Kawasaki A; Tsuchiya N; Fukazawa T; Hashimoto H; Tokunaga K
    Genes Immun; 2002 Nov; 3(7):424-9. PubMed ID: 12424625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated levels of soluble fractalkine in active systemic lupus erythematosus: potential involvement in neuropsychiatric manifestations.
    Yajima N; Kasama T; Isozaki T; Odai T; Matsunawa M; Negishi M; Ide H; Kameoka Y; Hirohata S; Adachi M
    Arthritis Rheum; 2005 Jun; 52(6):1670-5. PubMed ID: 15934075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus.
    Anolik JH; Barnard J; Cappione A; Pugh-Bernard AE; Felgar RE; Looney RJ; Sanz I
    Arthritis Rheum; 2004 Nov; 50(11):3580-90. PubMed ID: 15529346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.